Author

A. Deneka

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

E. A. Golemis· 2 shared A. C. Lilly· 1 shared A. Efimov· 1 shared A. Klochkova· 1 shared A. M. Charles Solomon· 1 shared A. Sipman· 1 shared A. Surumbayeva· 1 shared B. Bayarmagnai· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. A. Golemis

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer growth and immune suppression via phospholipid scramblase anoctamin 6 (ANO6).

C. Ogier, A. M. Charles Solomon, Z. Lu, L. Recoules, A. Klochkova, L. Gabitova-Cornell, B. Bayarmagnai, D. Restifo, A. Surumbayeva, D. B. Vendramini-Costa, A. Deneka, R. Francescone, A. C. Lilly, A. Sipman, J. C. Gardiner, , I. Astsaturov

This study identifies ANO6-mediated trogocytosis as a mechanism by which CAFs transfer lipids to PDAC cells, promoting tumor growth and immune suppression.

bioRxiv · Sep 15, 2023 · PreprintCancer Biology

Musashi-2 (MSI2) regulation of DNA damage response in lung cancer

I. Bychkov, A. Deneka, I. Topchu, R. P. Pangeni, C. Lengner, J. Karanicolas, E. A. Golemis, P. Makhov, Y. Boumber

This study shows MSI2 promotes lung tumorigenesis by enhancing ATM expression and DNA damage response, suggesting MSI2 as a potential therapeutic target in lung cancer.

bioRxiv · Jun 13, 2023 · PreprintCancer Biology